Table 1. Transplant Patient Characteristics.
| Recipient characteristics | Pt. 1 | Pt. 2 | Pt. 3 | Pt. 4 | Pt. 5 | Pt. 6 | Pt. 7 | Pt. 8 | Pt. 9 | Pt. 10 |
| Age | 67 | 41 | 44 | 29 | 65 | 58 | 41 | 67 | 44 | 60 |
| Sex | M | M | M | F | M | M | M | M | F | F |
| Race/Ethnicity | Black | White | Filipino | White | White | Hispanic | Asian | Hispanic | Black | White |
Type of renal disease
|
HTN | HTN | HTN | HUS | Type 2 DM | HTN & MPGN | IgA | UNK | HTN & ?GN | Type 1 DM |
| Thymoglobulin Induction | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Donor # | DD | DD | DD | Living | DD | DD | Living | DD | Living | Living |
| Conversion * | No | Sirolim-us | Sirolim-us | No | No | Sirolim-us | Sirolim-us | No | Sirolim-us | No |
| MPA dose/level at 12 weeks † | 2gm/0.8 | 1.25gm/5.0 | 2gm/2.2 | 2gm/4.2 | 2gm/2.9 | 1.5gm/3.0 | 3gm/2.4 | 3gm/3.3 | 2gm/1.2 | |
| Rejection (Yes/No) | Yes | Yes | No | No | No | No | No | No | No | No |
| Type of Rejection | Banff 1b‡ | Banff 1a | None | None | None | None | None | None | None | None |
| Rejection months Post-Tx | 10 | 7 | None | None | None | None | None | None | None | None |
| Creatinine - Month 1 | 1.1 | 2 | 2 | 0.9 | 1.6 | 3.9 | 1.6 | 1.9 | 1.4 | 1.1 |
| Creatinine - Month 3 | 0.9 | 1.7 | 1.8 | 0.9 | 1.2 | 1.9 | 1.2 | NA | 1.0 | 1.2 |
| Creatinine – Month 12 | 1.8 | 3.0 | 1.8 | 0.8 | 1.7 | 1.6 | 1.2 | 1.5 | 1.0 | 1.3 |
HUS = Hemolytic Uremic Syndrome; Type 2 DM = Type 2 Diabetes Mellitus; IgA = IgA nephropathy; HTN = hypertension; MPGN = membranoproliferative GN; ?GN = glomerulonephritis of ? etiology; Type 1 DM = Type 1 Diabetes Mellitus;
†
MPA = Mycophenolic acid.
#
DD = Deceased donor.
‡
Banff = international classification schema for kidney transplant pathology. Banff 1a and 1b are different forms of acute tubulointerstitial cellular acute rejection.
*All patients were started on FK506/CellCept with no Prednisone. Conversions from FK506 to sirolimus were done at approximately 3 months post-transplant as tolerated.